BR112013020702A2 - preparação farmacêutica contendo selenita ou compostos contendo selenita para o tratamento de displasias cervicais ou carcinomas - Google Patents

preparação farmacêutica contendo selenita ou compostos contendo selenita para o tratamento de displasias cervicais ou carcinomas

Info

Publication number
BR112013020702A2
BR112013020702A2 BR112013020702A BR112013020702A BR112013020702A2 BR 112013020702 A2 BR112013020702 A2 BR 112013020702A2 BR 112013020702 A BR112013020702 A BR 112013020702A BR 112013020702 A BR112013020702 A BR 112013020702A BR 112013020702 A2 BR112013020702 A2 BR 112013020702A2
Authority
BR
Brazil
Prior art keywords
selenite
carcinomas
treatment
acid
pharmaceutical preparation
Prior art date
Application number
BR112013020702A
Other languages
English (en)
Other versions
BR112013020702B1 (pt
Inventor
Norbert Fuchs
Original Assignee
Selo Medical Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selo Medical Gmbh filed Critical Selo Medical Gmbh
Publication of BR112013020702A2 publication Critical patent/BR112013020702A2/pt
Publication of BR112013020702B1 publication Critical patent/BR112013020702B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

preparação farmacêutica contendo selenita ou compostos contendo selenita para o tratamento de displasias cervicais ou carcinomas a invenção refere-se às composições que contêm compostos contendo selenita e ácidos farmaceuticamente aceitáveis, selecionados de ácido cítrico, ácido acético, ácido málico, ácido carbônico, ácido sulfúrico, ácido nítrico, ácido clorídrico, ácidos de frutas ou misturas dos mesmos, para uso no tratamento de inflamações cervicais, diplasia e/ou carcinomas.
BR112013020702-7A 2011-02-16 2012-02-16 Preparação farmacêutica contendo selenita ou compostos contendo selenita para o tratamento de displasias cervicais ou carcinomas BR112013020702B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA201/2011 2011-02-16
ATA201/2011A AT511159A1 (de) 2011-02-16 2011-02-16 Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen
PCT/AT2012/000032 WO2012109685A1 (de) 2011-02-16 2012-02-16 Pharmazeutische zubereitung enthaltend selenit - oder selenithaltige verbindungen zur behandlung von cervix - dysplasien oder -karzinomen

Publications (2)

Publication Number Publication Date
BR112013020702A2 true BR112013020702A2 (pt) 2016-10-18
BR112013020702B1 BR112013020702B1 (pt) 2021-09-08

Family

ID=45807993

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020702-7A BR112013020702B1 (pt) 2011-02-16 2012-02-16 Preparação farmacêutica contendo selenita ou compostos contendo selenita para o tratamento de displasias cervicais ou carcinomas

Country Status (28)

Country Link
US (3) US10201566B2 (pt)
EP (1) EP2675432B1 (pt)
JP (1) JP5986110B2 (pt)
CN (2) CN107582563B (pt)
AR (1) AR085265A1 (pt)
AT (1) AT511159A1 (pt)
AU (1) AU2012219005B2 (pt)
BR (1) BR112013020702B1 (pt)
CA (1) CA2826999C (pt)
CL (1) CL2013002353A1 (pt)
CY (1) CY1117768T1 (pt)
EA (2) EA025419B1 (pt)
ES (1) ES2577150T3 (pt)
GE (1) GEP201606590B (pt)
HK (1) HK1243360A1 (pt)
HR (1) HRP20160891T1 (pt)
HU (1) HUE029811T2 (pt)
IL (1) IL227981A (pt)
ME (1) ME02422B (pt)
MX (1) MX342098B (pt)
PL (1) PL2675432T3 (pt)
PT (1) PT2675432T (pt)
RS (1) RS54952B1 (pt)
SI (1) SI2675432T1 (pt)
SM (1) SMT201600233B (pt)
TW (1) TWI538678B (pt)
UA (1) UA112767C2 (pt)
WO (1) WO2012109685A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012222956A1 (de) * 2012-12-12 2014-06-12 Beiersdorf Ag Kosmetische Zubereitungen mit Fließgrenze
EP3616693A1 (en) * 2018-08-28 2020-03-04 Selo Medical GmbH Therapy of high-risk human papillomavirus infections
US20220288109A1 (en) * 2019-08-30 2022-09-15 Musc Foundation For Research Development Sphingolipid-based selenium compounds, methods for their preparation, and pharmaceutical uses thereof, including as antitumor agents
EP3875083A1 (en) * 2020-03-03 2021-09-08 Selo Medical GmbH Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid
US20230233498A1 (en) * 2020-06-26 2023-07-27 Prothione, Llc Compositions and methods for the treatment of covid-19

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1112164A (en) 1977-08-02 1981-11-10 Joseph R. Levitt Therapeutic selenium compositions and the use thereof
US4512977A (en) 1979-10-18 1985-04-23 Lundy Research Laboratories, Inc. Therapeutic selenium compositions and the use thereof
IT1161213B (it) 1983-03-08 1987-03-18 Fcn Srl Composizioni farmaceutiche ad attivita' antineoplastica
US4762726A (en) 1983-12-30 1988-08-09 Kraft, Inc. Shelf stable acid food dressings containing fibrous protein complexes
US4668515A (en) 1984-03-06 1987-05-26 Paul Bankit Method and compositions for sodium selenite administration
US5389677B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US5153230A (en) 1989-10-06 1992-10-06 Perfective Cosmetics, Inc. Topical skin cream composition
US5182104A (en) 1991-07-16 1993-01-26 Stanley Marcus Topical virucidal composition for treatment of mucocutaneous tissue
WO1993017588A1 (en) 1992-03-11 1993-09-16 The Procter & Gamble Company Psyllium drink mix compositions containing granulated base
US5425944A (en) 1992-10-27 1995-06-20 Harich; Jakob Antimicrobial grapefruit extract
US5536497A (en) 1992-12-21 1996-07-16 The Research Foundation Of State University Of New York Fimbrial polypeptides useful in the prevention of periodontitis
DE4320694C2 (de) 1993-06-22 1999-11-11 Biosyn Arzneimittel Gmbh Vewendung von Selenverbindungen zur äußeren Anwendung bei Warzen
US5484612A (en) 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
DE4335441A1 (de) 1993-10-18 1995-04-20 Hans Dipl Chem Heide Mittel zur Gesundheitsvorsorge im Herz- Kreislaufsystem beim Menschen
US5512200A (en) 1994-04-18 1996-04-30 Thomas G. Bongard Low pH Acidic Compositions
DE4413839C1 (de) 1994-04-21 1995-10-19 Fritz Koch Pharma Gmbh Dr Med Kombinationspräparat
DE69629874T2 (de) 1995-06-07 2004-07-08 Life Science Labs, Inc., Minneapolis Selen enthaltende Zusammensetzung zur Reduzierung der Krebshäufigkeit und zur Verlängerung des Lebensalters
GB2323030A (en) 1997-03-12 1998-09-16 Essential Nutrition Ltd Dietary supplements for immunocompromised patients
US5999844A (en) * 1997-04-23 1999-12-07 Accumed International, Inc. Method and apparatus for imaging and sampling diseased tissue using autofluorescence
US6069152A (en) 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
GB9722361D0 (en) 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
IT1297080B1 (it) 1997-11-26 1999-08-03 Andrea Carnevali Composizione per il trattamento di ustioni, eritemi solari, abrasioni, piaghe e irritazioni cutanee
US6228347B1 (en) 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
FR2779720B1 (fr) 1998-06-12 2002-08-16 Galderma Rech Dermatologique Nouveaux composes diarylselenures et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie
US6120758A (en) 1998-07-16 2000-09-19 Shaklee Corporation Preservative system for topically applied products
FR2782642B1 (fr) 1998-08-31 2001-12-07 Xavier Forceville Utilisation du selenium pour le traitement de patients atteints d'un syndrome de reponse inflammatoire systemique (sirs), et composition pour la mise en oeuvre du traitement
US6114348A (en) 1999-03-10 2000-09-05 Weber; Paul J. Method of treating warts using tazarotene
WO2001085852A1 (de) 2000-05-10 2001-11-15 Ökopharm Forschungs- und Entwicklungs-GmbH Verfahren zur verringerung der oberfläche von siliziumdioxid
AT412758B (de) 2000-06-05 2005-07-25 Vis Vitalis Lizenz & Handels Verwendung einer selenithältigen lösung zur behandlung viraler erkrankungen
AT412448B (de) 2001-02-13 2005-03-25 Vis Vitalis Lizenz & Handels Verwendung von selenhältigen präparaten
AT412703B (de) * 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung

Also Published As

Publication number Publication date
EA033519B1 (ru) 2019-10-31
TW201309308A (zh) 2013-03-01
MX342098B (es) 2016-09-13
SI2675432T1 (sl) 2016-08-31
CN107582563A (zh) 2018-01-16
MX2013009459A (es) 2013-12-12
HRP20160891T1 (hr) 2016-09-23
CA2826999A1 (en) 2012-08-23
JP2014505708A (ja) 2014-03-06
JP5986110B2 (ja) 2016-09-06
EA025419B1 (ru) 2016-12-30
CN107582563B (zh) 2021-03-19
WO2012109685A1 (de) 2012-08-23
IL227981A0 (en) 2013-09-30
GEP201606590B (en) 2017-01-10
CY1117768T1 (el) 2017-05-17
BR112013020702B1 (pt) 2021-09-08
EP2675432B1 (de) 2016-04-20
CL2013002353A1 (es) 2014-06-27
US20130323328A1 (en) 2013-12-05
AT511159A1 (de) 2012-09-15
EA201691236A1 (ru) 2016-10-31
CA2826999C (en) 2019-01-15
US10201566B2 (en) 2019-02-12
US20200206262A1 (en) 2020-07-02
ES2577150T3 (es) 2016-07-13
SMT201600233B (it) 2016-08-31
AU2012219005B2 (en) 2016-08-25
US10543228B2 (en) 2020-01-28
EP2675432A1 (de) 2013-12-25
US20190125787A1 (en) 2019-05-02
EA201300910A1 (ru) 2014-02-28
UA112767C2 (uk) 2016-10-25
TWI538678B (zh) 2016-06-21
AU2012219005A1 (en) 2013-09-19
HK1243360A1 (zh) 2018-07-13
HUE029811T2 (hu) 2017-03-28
PT2675432T (pt) 2016-07-26
PL2675432T3 (pl) 2016-10-31
RS54952B1 (sr) 2016-11-30
ME02422B (me) 2016-09-20
CN103379899A (zh) 2013-10-30
AR085265A1 (es) 2013-09-18
IL227981A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
CR20120605A (es) Formulación tópica para un inhibidor de jak
PH12015502002B1 (en) Tripeptide epoxy ketone protease inhibitors
HUE043540T2 (hu) Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2012151248A3 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
BR112015018071A2 (pt) estra-1,3,5(10),16-tetraeno-3-carboxamidas
JO3326B1 (ar) مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد
MY179605A (en) Use of benzimidazole-proline derivatives
EP2910563A8 (en) Triterpene derivative and its anti-influenza use
BR112013020702A2 (pt) preparação farmacêutica contendo selenita ou compostos contendo selenita para o tratamento de displasias cervicais ou carcinomas
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
WO2013138628A3 (en) Injectable ibuprofen formulation
WO2015001163A3 (es) Nanopartículas lipídicas para la cicatrización de heridas
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
IN2014DN09240A (pt)
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
WO2012019428A8 (zh) 二苯甲醇类衍生物、其制备方法及其在医药上的应用
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol
BR112015023872A2 (pt) composição compreendendo arabinogalactano e poliofenóis de árvores de lariço

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/02/2012, OBSERVADAS AS CONDICOES LEGAIS.